nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.09.2022 | editorial

Neoadjuvant treatment for solid tumors—the earlier, the better

verfasst von: Univ.-Prof. Dr. Rupert Bartsch, Prof. Dr. Wolfgang Hilbe

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Excerpt

Administering adjuvant systemic treatment following local therapy aiming to reduce recurrence rates and mortality is a standard approach in many common malignancies such as breast, colorectal, or lung cancer. Of note, administering systemic treatment already before surgery offers potential additional advantages such as downstaging and downsizing of the primary tumor and regional lymph nodes, in vivo sensitivity testing, earliest possible treatment of potential micrometastatic disease, and response-adapted tailoring of further postoperative therapy. …

Vorheriger Artikel Molecular profiling leading to personalized cancer treatment

Nächster Artikel Real time experience applying CAR T-cells for B-cell lymphoma—What we have learned so far: Acute toxicity management

Pusch R. Neoadjuvant treatment in solid tumors—the earlier, the better breast cancer. memo. 2022; https://doi.org/10.1007/s12254-022-00819-4.CrossRef

Sonnweber B, Schaber M, Wöll E. Neoadjuvant treatment in gastric cancer. memo. 2022; https://doi.org/10.1007/s12254-022-00823-8.CrossRef

Terbuch A, Absenger G. Neoadjuvant treatment in non-small-cell-lung-cancer—the earlier, the better. memo. 2022; https://doi.org/10.1007/s12254-022-00819-4.CrossRef

Kosma K, Thalhammer S, Grünberger T. Neoadjuvant treatment of pancreatic ductal adenocarcinoma. memo. 2022; https://doi.org/10.1007/s12254-022-00832-7.CrossRef

Titel: Neoadjuvant treatment for solid tumors—the earlier, the better
verfasst von: Univ.-Prof. Dr. Rupert Bartsch
Prof. Dr. Wolfgang Hilbe
Publikationsdatum: 01.09.2022
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 3/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-022-00835-4

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

Breast implant-associated anaplastic large-cell lymphoma—update on challenges, advances and opportunities

Neoadjuvant treatment of pancreatic ductal adenocarcinoma

CAR T cells in multiple myeloma: Where we stand and where we might be going

Publisher Correction: Brain metastases: new systemic treatment approaches

Neoadjuvant treatment in solid tumors—the earlier, the better in breast cancer

CAR-T cells—Real-time experience applying CAR-T cells—What we have learned so far